Clinical Commissioning Policy: Anakinra/tocilizumab for the treatment of Adult-Onset Still’s Disease refractory to second-line therapy (adults)

Document first published:
Page updated:
Topic:
,
Publication type:

This policy document outlines the arrangements for funding of treatment for adult-onset still’s disease refractory to second-line therapy.